Compare Gigacloud Technology Inc (GCT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Merck & Co., Inc. — how do they compare? Gigacloud Technology Inc trades at $56.37 (market cap $2.02B), while Merck & Co., Inc. trades at $145.12 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 173.9× Gigacloud Technology Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and Merck & Co., Inc. for 98 Days on average.
| GCT | MRK | |
|---|---|---|
Market Cap | $2.02B | $351.28B |
Volume | 1,020,985 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $56.42 | $156.43 |
52-Week Low | $25.46 | $82.49 |
Typical Hold Time | 21 Days | 98 Days |
Enterprise Value | $2.14B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GigaCloud Technology (GCT) trades at $55.65, down 0.55% on the day, with a bullish technical outlook from moving averages and a consensus analyst rating of Buy. The stock shows strong fundamentals with a P/E of 13.44, net income margin of 10.65%, and consistent earnings beats in recent quarters. Revenue is projected to grow from $1.29B in 2025 to $1.5B in 2026, while operating cash flow remains robust at $190.66M.
The investment outlook is positive given valuation attractiveness and earnings momentum, but risks include insider selling and reliance on international expansion. Analyst price targets suggest potential upside to $32.50 consensus, though the current price exceeds this, indicating mixed signals. Key catalysts are EU market growth and continued execution against guidance.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
